Most patients diagnosed with advanced stages of NSCLC with EGFR mutations are treated with TKIs, but they often develop secondary resistance to drugs such as dasatinib, erlotinib, and osimertinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.